HK1129071A1 - Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels - Google Patents

Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels

Info

Publication number
HK1129071A1
HK1129071A1 HK09108892.3A HK09108892A HK1129071A1 HK 1129071 A1 HK1129071 A1 HK 1129071A1 HK 09108892 A HK09108892 A HK 09108892A HK 1129071 A1 HK1129071 A1 HK 1129071A1
Authority
HK
Hong Kong
Prior art keywords
cholesterol
glucose levels
reducing triglyceride
indazolemethoxyalkanoic
acid
Prior art date
Application number
HK09108892.3A
Other languages
English (en)
Inventor
Angelo Guglielmotti
Giuseppe Biondi
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of HK1129071A1 publication Critical patent/HK1129071A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mixers Of The Rotary Stirring Type (AREA)
HK09108892.3A 2006-11-24 2009-09-25 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels HK1129071A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT002254A ITMI20062254A1 (it) 2006-11-24 2006-11-24 Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
PCT/EP2007/009908 WO2008061671A2 (en) 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels

Publications (1)

Publication Number Publication Date
HK1129071A1 true HK1129071A1 (en) 2009-11-20

Family

ID=38198404

Family Applications (2)

Application Number Title Priority Date Filing Date
HK09108892.3A HK1129071A1 (en) 2006-11-24 2009-09-25 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
HK12105854.0A HK1165275A1 (en) 2006-11-24 2012-06-15 Use of an indazolemethoxyalkanoic acid to prepare a pharmaceutical composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK12105854.0A HK1165275A1 (en) 2006-11-24 2012-06-15 Use of an indazolemethoxyalkanoic acid to prepare a pharmaceutical composition

Country Status (24)

Country Link
US (2) US8198310B2 (ru)
EP (2) EP2097080B1 (ru)
JP (1) JP5192490B2 (ru)
KR (1) KR101413616B1 (ru)
CN (1) CN101541323B (ru)
AR (1) AR063894A1 (ru)
AU (1) AU2007323351B2 (ru)
BR (1) BRPI0718522A2 (ru)
CA (1) CA2666371C (ru)
CY (1) CY1116664T1 (ru)
DK (2) DK2097080T3 (ru)
EA (1) EA016885B1 (ru)
ES (2) ES2530623T3 (ru)
GE (1) GEP20125570B (ru)
HK (2) HK1129071A1 (ru)
IL (1) IL198286A (ru)
IT (1) ITMI20062254A1 (ru)
MX (1) MX2009004295A (ru)
PL (2) PL2409698T3 (ru)
PT (2) PT2409698E (ru)
SG (1) SG176508A1 (ru)
SI (2) SI2097080T1 (ru)
UA (1) UA97123C2 (ru)
WO (1) WO2008061671A2 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20062254A1 (it) 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
PL2462118T3 (pl) 2009-08-03 2014-10-31 Acraf Sposób wytwarzania 1-benzylo-3-hydroksymetylo-1H-indazolu i jego pochodnych oraz potrzebnych magnezowych związków pośrednich
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
HUE049518T2 (hu) * 2014-05-15 2020-09-28 Translatum Medicus Inc Készítmények és eljárások a szem megbetegedéseinek kezelésére és diagnosztizálására
CA3144861A1 (en) 2019-06-25 2020-12-30 Translatum Medicus, Inc. Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1131779B (it) * 1980-07-29 1986-06-25 Acraf Sale dell'acido (1-benzil-1h-indazol-3-il)-ossiacetico con la lisina e procedimento per la sua preparazione
IT1230441B (it) * 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
IT1253703B (it) * 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
IT1276031B1 (it) * 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
IT1293794B1 (it) 1997-07-28 1999-03-10 Acraf Farmaco attivo nel ridurre la produzione di proteina mcp-1
EP2574336A1 (en) * 1998-02-02 2013-04-03 Trustees Of Tufts College Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
DE19821625C1 (de) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
ITFI20010230A1 (it) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
US20060030582A1 (en) * 2002-04-29 2006-02-09 Demartino Julie Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
CA2605900A1 (en) * 2005-04-29 2006-11-09 Nycomed Gmbh Mutual prodrug compounds for use as antiinflammatory agents with gastrointestinal protective activity
US8318657B2 (en) * 2005-12-01 2012-11-27 Flinders Technologies Pty Ltd. Methods and compositions for preventing and/or treating pancreatitis
ITMI20062254A1 (it) 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca

Also Published As

Publication number Publication date
CY1116664T1 (el) 2017-03-15
KR101413616B1 (ko) 2014-07-01
IL198286A (en) 2016-03-31
AR063894A1 (es) 2009-02-25
CN101541323A (zh) 2009-09-23
MX2009004295A (es) 2009-05-05
PL2097080T3 (pl) 2013-07-31
PL2409698T3 (pl) 2015-06-30
EP2409698A1 (en) 2012-01-25
DK2409698T3 (en) 2015-04-27
GEP20125570B (en) 2012-07-10
EP2409698B1 (en) 2015-01-21
KR20090081410A (ko) 2009-07-28
BRPI0718522A2 (pt) 2013-11-12
ITMI20062254A1 (it) 2008-05-25
IL198286A0 (en) 2010-02-17
US20100069456A1 (en) 2010-03-18
SG176508A1 (en) 2011-12-29
CA2666371A1 (en) 2008-05-29
SI2409698T1 (sl) 2015-04-30
EA200970506A1 (ru) 2009-10-30
JP2010510263A (ja) 2010-04-02
US8846745B2 (en) 2014-09-30
WO2008061671A3 (en) 2008-11-27
ES2530623T3 (es) 2015-03-04
AU2007323351A1 (en) 2008-05-29
DK2097080T3 (da) 2013-05-21
HK1165275A1 (en) 2012-10-05
PT2409698E (pt) 2015-02-10
US8198310B2 (en) 2012-06-12
PT2097080E (pt) 2013-04-01
CN101541323B (zh) 2012-01-04
EP2097080A2 (en) 2009-09-09
AU2007323351B2 (en) 2013-05-02
US20120283307A1 (en) 2012-11-08
EP2097080B1 (en) 2013-02-20
ES2403584T3 (es) 2013-05-20
SI2097080T1 (sl) 2013-05-31
WO2008061671A2 (en) 2008-05-29
EA016885B1 (ru) 2012-08-30
CA2666371C (en) 2014-05-06
UA97123C2 (ru) 2012-01-10
JP5192490B2 (ja) 2013-05-08

Similar Documents

Publication Publication Date Title
MX2009003958A (es) Nuevos derivados de 1,4-benzotiepina-1,1-dioxido sustituidos con radicales bencilo, metodo para su preparacion, productos farmaceuticos que comprenden estos compuestos y su uso.
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
MY142830A (en) Propionic acid derivatives useful in the treatment of lipid disorders
TW200833663A (en) Therapeutic agents
WO2008124085A3 (en) Methods of using combinations of mek and jak-2 inhibitors
BRPI0511327A (pt) combinações de glicopirrolato e agonistas do adrenorreceptor beta2
WO2010093849A3 (en) Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
WO2009063202A3 (en) Use of crth2 antagonist compounds
MX2011012122A (es) Derivados de tiofeno.
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
SG155961A1 (en) Pyrazoles as 11-beta-hsd-1
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
WO2007135527A3 (en) Benzimidazolyl compounds
WO2007138472A3 (en) Triazolopyridazine derivatives
MY148096A (en) 4,5-diphenyl-pyrimidinyl-amino substituted carboxylic acids, method for the production and use thereof as medicaments
MX2008009413A (es) Heterociclos como agonistas del receptor de acido nicotinico para el tratamiento de la dislipidemia.
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
WO2007024843A3 (en) Pyrimidinyl-pyrazole inhibitors of aurora kinases
WO2006077025A3 (en) Morpholines as 5ht2c agonists
NO20050667L (no) N-substituerte-1H-indol-5-propionsyreforbindelser som PPAR agonister nyttige for behandling av diabetes
WO2006124413A3 (en) Methods for treating drug resistant cancer
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
BRPI0905687A2 (pt) "composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto"

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20181112